drugset / Trial / NCT00477035
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
NaSingle-groupOpen-labelPrevention
Summary
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with high-risk hematologic malignancies.
Timeline
- Start
- 2006-05
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | 2e+08 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 100 mg/kg | — |
| Background | Etoposide | Small molecule | 60 mg/kg | — |
| Background | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Background | Melphalan | Small molecule | 200 mg/m2 | — |
| Background | Vinorelbine | Small molecule | 30 mg/m2 | — |
| Background | carmustine | Small molecule | 15 mg/kg | — |